[go: up one dir, main page]

MX2014006629A - Inhibidores de cinasa. - Google Patents

Inhibidores de cinasa.

Info

Publication number
MX2014006629A
MX2014006629A MX2014006629A MX2014006629A MX2014006629A MX 2014006629 A MX2014006629 A MX 2014006629A MX 2014006629 A MX2014006629 A MX 2014006629A MX 2014006629 A MX2014006629 A MX 2014006629A MX 2014006629 A MX2014006629 A MX 2014006629A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
diseases
compounds
useful
formula
Prior art date
Application number
MX2014006629A
Other languages
English (en)
Other versions
MX351958B (es
Inventor
Elisabetta Armani
Monique Bodil Van Niel
Nicholas Charles Ray
Lilian Alcaraz
Terry Aaron Panchal
Andrew Stephen Robert Jennings
Andrew Peter Cridland
Christopher Hurley
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MX2014006629A publication Critical patent/MX2014006629A/es
Publication of MX351958B publication Critical patent/MX351958B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I): (ver Fórmula) o una sal del mismo farmacéuticamente aceptable; en donde R2, W, A, Y, y R1 tienen los valores definidos en la especificación, que son inhibidores de la MAPK p38, útiles corno agentes anti-inflamatorios en el tratamiento de entre otras, enfermedades del tracto respiratorio.
MX2014006629A 2011-12-09 2012-12-05 Inhibidores de cinasa. MX351958B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11192894 2011-12-09
EP12187932 2012-10-10
PCT/EP2012/074450 WO2013083606A1 (en) 2011-12-09 2012-12-05 Kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014006629A true MX2014006629A (es) 2014-07-09
MX351958B MX351958B (es) 2017-11-06

Family

ID=47469888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006629A MX351958B (es) 2011-12-09 2012-12-05 Inhibidores de cinasa.

Country Status (18)

Country Link
US (2) US8835431B2 (es)
EP (1) EP2788348B1 (es)
JP (1) JP6145849B2 (es)
KR (1) KR20140105459A (es)
CN (1) CN103974953B (es)
AR (1) AR089113A1 (es)
AU (1) AU2012347352B2 (es)
BR (1) BR112014013177A2 (es)
CA (1) CA2860479A1 (es)
IL (1) IL232959A (es)
MX (1) MX351958B (es)
MY (1) MY167216A (es)
PH (1) PH12014501278B1 (es)
RU (1) RU2623734C9 (es)
SG (2) SG10201604656YA (es)
TW (1) TWI568732B (es)
WO (1) WO2013083606A1 (es)
ZA (1) ZA201404157B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013178A2 (pt) * 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
SG10201604656YA (en) * 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
PT2788349T (pt) 2011-12-09 2017-02-02 Chiesi Farm Spa Inibidores de cinase
BR112015029970A2 (pt) * 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
EP3394059B1 (en) * 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
US10364245B2 (en) * 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
RU2676692C1 (ru) * 2018-08-01 2019-01-10 Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации Способ получения n-фенил-2-нафтиламина

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
EP1458682B1 (en) 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
EP1601672B1 (en) * 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
RU2006108864A (ru) * 2003-08-22 2007-09-27 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
PT1761520E (pt) 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
DE602005010714D1 (de) 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP1891047A4 (en) 2005-06-03 2008-07-09 Bayer Healthcare Ag A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER
CA2642209A1 (en) * 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CL2007002867A1 (es) 2006-10-04 2008-06-27 Pharmacopeia Inc Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CN101636397B (zh) 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途
JP5569857B2 (ja) 2007-08-10 2014-08-13 アステラス製薬株式会社 二環式アシルグアニジン誘導体
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
CA2726102A1 (en) 2008-06-11 2009-12-17 Actelion Pharmaceuticals Ltd Tetrazole compounds as orexin receptor antagonists
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
SG171993A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
JP2012517992A (ja) * 2009-02-17 2012-08-09 チェシ ファーマスーティシ エス．ピー．エイ． Ｐ３８ｍａｐキナーゼインヒビターとしてのトリアゾロピリジン誘導体
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US8721380B2 (en) 2009-08-12 2014-05-13 Konica Minolta Holdings, Inc. Method for manufacturing display panel
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) * 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
BR112014013178A2 (pt) * 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
PT2788349T (pt) * 2011-12-09 2017-02-02 Chiesi Farm Spa Inibidores de cinase
SG10201604656YA (en) * 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors

Also Published As

Publication number Publication date
ZA201404157B (en) 2015-12-23
US9029373B2 (en) 2015-05-12
IL232959A0 (en) 2014-08-03
US8835431B2 (en) 2014-09-16
SG11201402986RA (en) 2014-12-30
RU2623734C9 (ru) 2017-09-18
CN103974953A (zh) 2014-08-06
WO2013083606A1 (en) 2013-06-13
CA2860479A1 (en) 2013-06-13
CN103974953B (zh) 2016-06-29
SG10201604656YA (en) 2016-07-28
EP2788348B1 (en) 2016-10-19
HK1199873A1 (en) 2015-07-24
US20140343055A1 (en) 2014-11-20
PH12014501278A1 (en) 2014-09-08
MY167216A (en) 2018-08-14
JP6145849B2 (ja) 2017-06-14
BR112014013177A2 (pt) 2017-06-13
JP2015502948A (ja) 2015-01-29
RU2014123031A (ru) 2016-01-27
MX351958B (es) 2017-11-06
EP2788348A1 (en) 2014-10-15
TW201331200A (zh) 2013-08-01
US20130150361A1 (en) 2013-06-13
RU2623734C2 (ru) 2017-06-29
IL232959A (en) 2016-11-30
AU2012347352A1 (en) 2014-07-03
AU2012347352B2 (en) 2016-12-15
TWI568732B (zh) 2017-02-01
AR089113A1 (es) 2014-07-30
KR20140105459A (ko) 2014-09-01
PH12014501278B1 (en) 2014-09-08

Similar Documents

Publication Publication Date Title
PH12014501277A1 (en) Kinase inhibitors
PH12014501278A1 (en) Kinase inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
UA111382C2 (uk) Інгібітори протеїнкінази
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
AU2012214029A8 (en) Rorgammat inhibitors
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JO2885B1 (en) Protein kinase inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
EA201792116A1 (ru) Ингибитор янус-киназы
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
GB201209587D0 (en) Therapeutic compounds
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
TN2014000218A1 (en) Kinase inhibitors
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
TH131154A (th) อนุพันธ์ยูเรียซึ่งเป็นสารยับยั้งไคเนสและการใช้อนุพันธ์ดังกล่าวทางการบำบัด
UA110849C2 (uk) Сполуки для лікування та профілактики респіраторного синцитіального вірусного захворювання

Legal Events

Date Code Title Description
FG Grant or registration